Sanofi Enters Next Chapter of Play to Win Strategy

Media Update: Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E.coli (ExPEC)


Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease